Better Vision.
Dedicated to deliver superior vision for fuller and healthier lives
Better vision is fundamental to living a healthier life.
For people with vision-threatening diseases, including wet age-related macular degeneration (wet AMD), achieving the best vision possible is essential to engage in daily activities and enjoy a fuller life.
Elevating the current standard of care in wet AMD
Our team is working to achieve the unprecedented – delivery of superior vision to patients with wet AMD by developing its novel, first-in-class anti-VEGF-C/D ‘trap’ inhibitor in combination with current standard-of-care anti-VEGF-A therapies.
Dedicated to Achieving the Unprecedented
Sozinibercept is the only product in late-stage clinical development for wet AMD that in combination with an anti-VEGF-A has the potential to be the first therapy in 20 years to deliver superior visual outcomes to patients suffering from this debilitating disease.
In a large Phase 2b clinical trial of 366 treatment-naïve wet AMD patients, sozinibercept demonstrated clinical evidence of superior visual outcomes in combination with standard-of-care ranibizumab*.
Sozinibercept is currently being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST and ShORe) designed to assess the safety and superior efficacy of sozinibercept combination therapy versus standard-of-care anti-VEGF-A therapies for the treatment of wet AMD. Topline results for COAST are expected in early Q2/2025 and for ShORe in mid 2025.
*Lucentis
Our Science Based on Bold Innovation
Sozinibercept combination therapy has the potential to elevate the standard of care by delivering superior visual outcomes.
Current standard-of-care therapies have transformed the treatment of wet AMD by primarily inhibiting vascular endothelial growth factor A (VEGF-A), a member of the VEGF signalling pathway which contributes to the pathophysiology of retinal diseases, including wet AMD.
The VEGF-C and VEGF-D signaling pathways are also important in the pathogenesis of retinal diseases, and evidence shows they are upregulated following VEGF-A suppression. Blocking VEGF-A alone therefore may contribute to an incomplete response.
Sozinibercept is a novel, first-in-class VEGF-C/D ‘trap’ inhibitor designed to be used in combination with standard-of-care anti-VEGF-A therapies, with the potential to deliver superior visual outcomes.
